MBIO - Mustang Bio launches early-stage CAR T therapy study in brain tumor

Mustang Bio ([[MBIO]] +5.7%) has initiated Phase 1 single-center, two-arm clinical trial evaluating MB-101 (autologous IL13R?2-CAR T cells) in leptomeningeal brain tumors (e.g., glioblastoma, ependymoma or medulloblastoma).The 30-subject trial will establish the safety and feasibility of administering MB-101 through the ICV Rickham catheter over four weekly cycles in patients with glioblastoma (Arm 1) and ependymoma or medulloblastoma (Arm 2). Primary endpoints that will be evaluated are toxicity and survival at three months. Secondary endpoints include overall survival, CAR T and endogenous T cell levels, cytokine levels and phenotype detection in peripheral blood, tumor cyst fluid and cerebrospinal fluid.IL13R?2 is overexpressed on the surface of the majority of malignant glioma cells. MB-101 is designed as an optimized CAR T product incorporating enhancements in CAR design and T cell engineering to improve antitumor potency and T cell persistence.

For further details see:

Mustang Bio launches early-stage CAR T therapy study in brain tumor